Barclays Reaffirms Their Buy Rating on Edwards Lifesciences (EW)

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Edwards Lifesciences (EW – Research Report), with a price target of $100.00. The company’s shares closed yesterday at $88.01.

According to TipRanks, Miksic is a 5-star analyst with an average return of 6.8% and a 60.00% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Medtronic, Baxter International, and LivaNova.

In addition to Barclays, Edwards Lifesciences also received a Buy from TD Cowen’s Josh Jennings in a report issued on April 23. However, on April 17, Leerink Partners reiterated a Hold rating on Edwards Lifesciences (NYSE: EW).

Based on Edwards Lifesciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.53 billion and a net profit of $369.9 million. In comparison, last year the company earned a revenue of $1.35 billion and had a net profit of $398.4 million

Based on the recent corporate insider activity of 116 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EW in relation to earlier this year. Most recently, in February 2024, Kieran Gallahue, a Director at EW bought 7,056.00 shares for a total of $260,084.16.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Edwards Lifesciences (EW) Company Description:

Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.